Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AVXLNASDAQ:DAWNNASDAQ:REPLNASDAQ:VYGR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVXLAnavex Life Sciences$7.63+0.7%$8.57$3.51▼$14.44$651.39M0.821.23 million shs747,992 shsDAWNDay One Biopharmaceuticals$6.48+2.7%$7.08$6.08▼$16.76$656.83M-1.241.11 million shs946,344 shsREPLReplimune Group$9.37+11.2%$8.42$4.93▼$17.00$722.31M0.68933,981 shs2.42 million shsVYGRVoyager Therapeutics$2.82+3.3%$3.27$2.71▼$9.55$156.05M0.95441,160 shs278,742 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVXLAnavex Life Sciences+0.66%-0.52%-20.77%-3.54%+96.14%DAWNDay One Biopharmaceuticals+2.69%+3.35%-15.63%-28.48%-52.91%REPLReplimune Group+11.15%+6.96%-0.21%-26.10%+87.03%VYGRVoyager Therapeutics+3.30%-5.69%-21.45%-30.88%-63.94%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAVXLAnavex Life Sciences3.7912 of 5 stars3.70.00.04.73.60.80.6DAWNDay One Biopharmaceuticals2.5974 of 5 stars4.60.00.00.03.02.50.0REPLReplimune Group4.0954 of 5 stars3.61.00.04.53.12.50.6VYGRVoyager Therapeutics4.6447 of 5 stars4.62.00.04.61.61.71.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVXLAnavex Life Sciences 3.33Buy$44.00476.67% UpsideDAWNDay One Biopharmaceuticals 3.13Buy$30.57371.78% UpsideREPLReplimune Group 3.13Buy$19.43107.35% UpsideVYGRVoyager Therapeutics 3.13Buy$13.39374.82% UpsideCurrent Analyst Ratings BreakdownLatest VYGR, REPL, AVXL, and DAWN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/7/2025DAWNDay One BiopharmaceuticalsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$25.005/7/2025DAWNDay One BiopharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$30.00 ➝ $27.004/8/2025VYGRVoyager TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.00 ➝ $30.004/7/2025AVXLAnavex Life SciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$42.00 ➝ $42.004/7/2025AVXLAnavex Life SciencesD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$46.00 ➝ $46.004/3/2025DAWNDay One BiopharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$36.00 ➝ $36.003/31/2025AVXLAnavex Life SciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$42.00 ➝ $42.003/25/2025DAWNDay One BiopharmaceuticalsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$39.00 ➝ $27.003/13/2025VYGRVoyager TherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$14.00 ➝ $12.003/13/2025VYGRVoyager TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.00 ➝ $30.003/12/2025VYGRVoyager TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetOverweight ➝ Overweight$12.00 ➝ $10.00(Data available from 5/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVXLAnavex Life SciencesN/AN/AN/AN/A$1.42 per shareN/ADAWNDay One Biopharmaceuticals$161.92M4.06N/AN/A$3.98 per share1.63REPLReplimune GroupN/AN/AN/AN/A$6.26 per shareN/AVYGRVoyager Therapeutics$66.96M2.33$2.00 per share1.41$5.37 per share0.53Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVXLAnavex Life Sciences-$43M-$0.55N/AN/AN/AN/A-37.50%-34.08%8/5/2025 (Estimated)DAWNDay One Biopharmaceuticals-$188.92M-$0.71N/AN/AN/AN/A-22.40%-19.79%7/8/2025 (Estimated)REPLReplimune Group-$215.79M-$3.07N/AN/AN/AN/A-54.84%-42.97%8/6/2025 (Estimated)VYGRVoyager Therapeutics$132.33M-$1.463.97N/AN/A15.80%8.33%6.15%8/5/2025 (Estimated)Latest VYGR, REPL, AVXL, and DAWN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/22/2025Q4 2025REPLReplimune Group-$0.75-$0.82-$0.07-$0.82N/AN/A5/13/2025Q2 2025AVXLAnavex Life Sciences-$0.16-$0.13+$0.03-$0.13N/AN/A5/6/2025Q1 2025DAWNDay One Biopharmaceuticals-$0.46-$0.35+$0.11-$0.35$30.28 million$30.76 million5/6/2025Q1 2025VYGRVoyager Therapeutics-$0.35-$0.53-$0.18-$0.53$13.55 million$6.47 million3/11/2025Q4 2024VYGRVoyager Therapeutics-$0.35-$0.59-$0.24-$0.59$16.58 million$4.39 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAVXLAnavex Life SciencesN/AN/AN/AN/AN/ADAWNDay One BiopharmaceuticalsN/AN/AN/AN/AN/AREPLReplimune GroupN/AN/AN/AN/AN/AVYGRVoyager TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVXLAnavex Life SciencesN/A9.459.45DAWNDay One BiopharmaceuticalsN/A14.6214.55REPLReplimune Group0.1411.4311.43VYGRVoyager TherapeuticsN/A8.458.45Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVXLAnavex Life Sciences31.55%DAWNDay One Biopharmaceuticals87.95%REPLReplimune Group92.53%VYGRVoyager Therapeutics48.03%Insider OwnershipCompanyInsider OwnershipAVXLAnavex Life Sciences11.00%DAWNDay One Biopharmaceuticals6.20%REPLReplimune Group8.80%VYGRVoyager Therapeutics6.39%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVXLAnavex Life Sciences4085.37 million75.71 millionOptionableDAWNDay One Biopharmaceuticals60101.36 million92.38 millionOptionableREPLReplimune Group21077.09 million70.24 millionOptionableVYGRVoyager Therapeutics10055.34 million52.15 millionOptionableVYGR, REPL, AVXL, and DAWN HeadlinesRecent News About These Companies2001: A Space Odyssey's balletic waltz to be beamed to Voyager 1May 27 at 4:49 AM | newatlas.comNASA restarts one of Voyager 1's thrusters after 21 years of inactivityMay 26, 2025 | lemonde.frVestal Point Capital LP Raises Stock Position in Voyager Therapeutics, Inc. (NASDAQ:VYGR)May 21, 2025 | marketbeat.comNASA Engineers Revive Long-Dormant Thrusters on Voyager 1, the Farthest Spacecraft From Earth, in a ‘Miracle Save’May 21, 2025 | msn.comVoyager Therapeutics' Role in Biotechnology and Market Trends NASDAQ CompositeMay 20, 2025 | kalkinemedia.comWith 46% ownership, Voyager Therapeutics, Inc. (NASDAQ:VYGR) has piqued the interest of institutional investorsMay 20, 2025 | uk.finance.yahoo.comVoyager Technologies files to go publicMay 19, 2025 | spacenews.comVoyager Therapeutics, Inc. (NASDAQ:VYGR) Receives Average Rating of "Buy" from BrokeragesMay 18, 2025 | marketbeat.comVoyager reports breakthrough in brain drug deliveryMay 17, 2025 | uk.investing.comVoyager Therapeutics Publishes Data on ALPL's Role in AAV Transport Across the Blood-Brain BarrierMay 15, 2025 | quiverquant.comVoyager Demonstrates ALPL Receptor-Mediated Blood-Brain Barrier Transport of Novel AAV Capsids in Molecular Therapy PublicationMay 15, 2025 | globenewswire.comVoyager Therapeutics, Inc. (NASDAQ:VYGR) Stake Decreased by Bridgeway Capital Management LLCMay 15, 2025 | marketbeat.comVoyager Therapeutics, Inc. (NASDAQ:VYGR) Stock Position Increased by Dimensional Fund Advisors LPMay 13, 2025 | marketbeat.comQ2 EPS Forecast for Voyager Therapeutics Reduced by AnalystMay 13, 2025 | marketbeat.comWhat is Leerink Partnrs' Forecast for VYGR Q2 Earnings?May 11, 2025 | marketbeat.comWedbush Equities Analysts Boost Earnings Estimates for VYGRMay 11, 2025 | marketbeat.comFarallon Capital Management LLC Has $14.58 Million Stock Holdings in Voyager Therapeutics, Inc. (NASDAQ:VYGR)May 11, 2025 | marketbeat.comWhat is Leerink Partnrs' Forecast for VYGR FY2029 Earnings?May 10, 2025 | marketbeat.comVoyager Therapeutics, Inc.: Voyager Reports First Quarter 2025 Financial and Operating ResultsMay 9, 2025 | finanznachrichten.deRaymond James Financial Inc. Takes $746,000 Position in Voyager Therapeutics, Inc. (NASDAQ:VYGR)May 9, 2025 | marketbeat.comNeurocrine hands back 2 CNS gene therapy programs to VoyagerMay 7, 2025 | fiercebiotech.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeVYGR, REPL, AVXL, and DAWN Company DescriptionsAnavex Life Sciences NASDAQ:AVXL$7.63 +0.05 (+0.66%) Closing price 05/29/2025 04:00 PM EasternExtended Trading$7.61 -0.02 (-0.25%) As of 05/29/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.Day One Biopharmaceuticals NASDAQ:DAWN$6.48 +0.17 (+2.69%) Closing price 05/29/2025 04:00 PM EasternExtended Trading$6.63 +0.15 (+2.38%) As of 04:05 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.Replimune Group NASDAQ:REPL$9.37 +0.94 (+11.15%) Closing price 05/29/2025 04:00 PM EasternExtended Trading$9.48 +0.11 (+1.12%) As of 05/29/2025 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.Voyager Therapeutics NASDAQ:VYGR$2.82 +0.09 (+3.30%) Closing price 05/29/2025 04:00 PM EasternExtended Trading$2.79 -0.03 (-1.10%) As of 05/29/2025 06:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Hormel Stock Near Lows, But Tariff Relief Could Boost Outlook Salesforce’s Stock Price Presents an Opportunity to Buy NVIDIA Will Set a New High Soon, Then Keep Rallying, Here’s Why Goodyear Stock Surges 28% in 2025: Is More Growth Ahead? Intel's Loss Is Broadcom's Gain as AVGO Dominates Networking Target's Big Bet: Is It a Cheap Stock or a Value Trap? Dividend Investors Looking for an Edge? 3 Stocks Insiders Bought Toyota Supercharges Joby: $250M Capital Infusion Ignites Stock Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
